Immune evasion mechanisms of Hepatitis C virus. Review;Mecanismos de evasión inmunitaria del virus de Hepatitis C. Revisión

Investigacion Clinica

Volumn 47, Issue 1, 2006, Pages

  Porto Espinoza, Leticia ^a,b   Cuadra Sánchez, César ^a   Moronta, Reyna ^a   Monsalve Castillo, Francisca ^a   Callejas Valero, Diana ^a  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Antigenic variation; Hepatitis C virus; Immune evasion; Viral immunosuppression

Indexed keywords

CORE PROTEIN; GLYCOPROTEIN E2; HEPATITIS C VACCINE; UNCLASSIFIED DRUG; VIRAL PROTEIN NS5A; VIRUS PROTEIN;

ANTIGENIC VARIATION; CHRONIC DISEASE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; REVIEW; GENETICS; IMMUNOLOGY; VIROLOGY;

HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; VARIATION (GENETICS);

EID: 33646492928     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Uriz J, Briz R. Natural history of hepatitis C virus infection. An Sist Sanit Navar 2004; 27(2):51-58.
2. Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options Oncol 2001; 2(6):473-483.
3. Ramos-Gómez M. Historia natural de la hepatitis crónica C. Rev Gastroenter 2002; 67(2):S17-S20.
4. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345(1): 41-52.
5. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34(4 Pt 1):809-816.
6. Kenny-Walsh E. The natural history of hepatitis C virus infection. Clin Liver Dis 2001; 5(4):969-77.
7. Polyak SJ. Hepatitis C virus - cell interactions and their role in pathogenesis. Clin Liver Dis 2003; 7(1):67-88.
8. Aguilar MS, Cosson C, Loureiro CL, Devesa M, Martinez J, Villegas L, Flores J, Ludert JE, Alarcon- Noya B, Noya O, Liprandi F, Pujol FH. Prevalence of infection with hepatitis C virus in Venezuela, as assessed with an immuno-assay based on synthetic peptides. Ann Trop Med Parasitol 2001; 95(2):187-195.
9. Arteaga-Vizcaino M, Blitz-Dorfman L, Echeverria JM, Leon P, Weir-Medina J, Diez-Ewald M, Vizcaino G, Torres E, Porto-Espinoza L. Hepatitis C in hemophiliac patients in Maracaibo, Venezuela. Invest Clin 1993; 34(3):113-118.
10. Feldman M, Friedman LS, Sleisenger MH. Sleisenger & Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. 7th ed. [CD-ROM]. Philadelphia: Saunders; 2002.
11. Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002; 17(4):423-430.
12. Mandell GL, Douglas RG, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. [CD-ROM]. Philadelphia: Churchill Livingstone; 2000.
13. Valiante NM, D'Andrea A, Crotta S, Lechner F, Klenerman P, Nuti S, Wack A, Abrignani S. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol Rev 2000; 174:77-89.
14. Alvarado-Esquivel C, Leroux-Roels G. Inmunología de la hepatitis C. Rev Invest Clin 1999; 51(5):315-322.
15. Dore GJ, Freeman AJ, Kaldor JM. Immunity against hepatitis C virus infection. Lancet 2002; 360(9338):1019-20; author reply 1020-1021.
16. Weiner AJ, Paliard X, Selby MJ, Medina-Selby A, Coit D, Nguyen S, Kansopon J, Arian CL, Ng P, Tucker J, Lee CT, Polakos NK, Han J, Wong S, Lu HH, Rosenberg S, Brasky KM, Chien D, Kuo G, Houghton M. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 2001; 75(15):7142-7148.
17. Lara-Ceniceros M, Godínez-Hernández F, Aillaud- González L, Mejía A. Hepatitis C. Med Int Mex 2003; 19(5):311-318.
18. Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol 2001; 44(2):159-182.
19. Rivas-Estilla A, Panduro A. Mecanismos moleculares del virus de la hepatitis C, potenciales blancos terapéuticos. Rev Invest Clin 2003; 55(1):51-64.
20. Álvarez M, Gómez I. Biología y métodos diagnósticos del virus de la hepatitis C. Rev Biomed 2003; 14(4):253-268.
21. Drazan KE. Molecular biology of hepatitis C infection. Liver Transpl 2000; 6(4):396-406.
22. Forns X. Molecular biology of hepatitis C virus: implications for the development of new therapies and prophylactic vaccine. Med Clin (Barc) 2001; 116(5):191-197.
23. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001; 79(6):515-536.
24. Montaño-Loza A, Meza-Junco J, Remes-Troche J. Patogénesis de la infección por virus de hepatitis C. Rev Invest Clin 2001; 53(6):561-568.
25. Terrés-Speziale AM. Hepatitis C. Historia natural y estado actual de su manejo. Rev Mex Patol Clin 2003; 50(4):179-189.
26. Hahn YS. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr Opin Immunol 2003; 15(4):443-449.
27. Somsouk M, Lauer GM, Casson D, Terella A, Day CL, Walker BD, Chung RT. Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology 2003; 124(7):1946-1949.
28. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2003; 7(1):89-105.
29. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74(3):360-369.
30. Gale M, Jr., Kwieciszewski B, Dossett M, Nakao H, Katze MG. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999; 73(8):6506-6516.
31. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14(4):778-809.
32. Polyak SJ, Paschal DM, McArdle S, Gale MJ, Jr., Moradpour D, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999; 29(4):1262-1271.
33. Gale MJ, Jr., Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 1998; 10(2-3):157-162.
34. Khabar KS, Polyak SJ. Hepatitis C virus-host interactions: the NS5A protein and the interferon/chemokine systems. J Interferon Cytokine Res 2002; 22(10): 1005-1012.
35. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195(1):35-41.
36. Miller K, McArdle S, Gale MJ, Jr., Geller DA, Tenoever B, Hiscott J, Gretch DR, Polyak SJ. Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res 2004; 24(7):391-402.
37. Ray RB, Ray R. Hepatitis C virus core protein: intriguing properties and functional relevance. FEMS Microbiol Lett 2001; 202(2):149-156.
38. Yao ZQ, Ray S, Eisen-Vandervelde A, Waggoner S, Hahn YS. Hepatitis C virus: immunosuppression by complement regulatory pathway. Viral Immunol 2001; 14(4):277-295.
39. Yao ZQ, Nguyen DT, Hiotellis AI, Hahn YS. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J Immunol 2001; 167(9):5264-5272.
40. Barnes E, Lauer G, Walker B, Klenerman P. T cell failure in hepatitis C virus infection. Viral Immunol 2002; 15(2):285-293.
41. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191(9):1499-1512.
42. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR, Klenerman P. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75(12):5550-5558.
43. Lucas M, Vargas-Cuero AL, Lauer GM, Barnes E, Willberg CB, Semmo N, Walker BD, Phillips R, Klenerman P. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol 2004; 172(3):1744-1753.
44. Lechner F, Sullivan J, Spiegel H, Nixon DF, Ferrari B, Davis A, Borkowsky B, Pollack H, Barnes E, Dusheiko G, Klenerman P. Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. Philos Trans R Soc Lond B Biol Sci 2000; 355(1400):1085-1092.
45. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000; 30(9):2479-2487.
46. Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128(2): 195-203.
47. Reiser M, Marousis CG, Nelson DR, Lauer G, Gonzalez-Peralta RP, Davis GL, Lau JY. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol 1997; 26(3): 471-478.
48. Monsalve-De Castillo F, Romero TA, Estevez J, Costa LL, Atencio R, Porto-Espinoza L, Callejas D. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol 2002; 9(6):1372-1375.
49. Monsalve F, Romero AT, Estevez J, Costa L, Callejas D. Serum levels of soluble CD30 molecule in hepatitis B virus infection. Rev Med Chil 2001; 129(11):1248-1252.
50. Soguero C, Joo M, Chianese-Bullock KA, Nguyen DT, Tung K, Hahn YS. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol 2002; 76(18):9345-9354.
51. Sarobe P, Lasarte JJ, Casares N, Lopez-Diaz de Cerio A, Baixeras E, Labarga P, Garcia N, Borras-Cuesta F, Prieto J. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002; 76(10):5062-5070.
52. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, Kim AY, Lucas M, Klenerman P, Walker BD. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76(12):6104-6113.
53. Nelson DR. The immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2001; 5(4):931-953.
54. Moradpour D, Grabscheid B, Kammer AR, Schmidtke G, Groettrup M, Blum HE, Cerny A. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology 2001; 33(5):1282-1287.
55. Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, Feinstone SM, Murthy KK, Rehermann B, Liang TJ. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003; 77(2):862-870.
56. Heo TH, Chang JH, Lee JW, Foung SK, Dubuisson J, Kang CY. Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein. J Immunol 2004; 173(1): 446-455.
57. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, Haber PS, Marinos G, Levy MH, Kaldor JM, Dolan KA, Ffrench RA, Lloyd AR, Rawlinson WD. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189(10):1846-1855.
58. Han JQ, Barton DJ. Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. 2002; 8(4):512-525.
59. Ray RB, Meyer K, Steele R, Shrivastava A, Aggarwal BB, Ray R. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 1998; 273(4):2256-2259.
60. Erdtmann L, Franck N, Lerat H, Le Seyec J, Gilot D, Cannie I, Gripon P, Hibner U, Guguen-Guillouzo C. The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis. J Biol Chem 2003; 278(20):18256-18264.
61. Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KM, Reichen J, Melief CJ, Cerny A. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999; 190(2):169-176.
62. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 1999; 162(2):931-938.
63. Sun J, Bodola F, Fan X, Irshad H, Soong L, Lemon SM, Chan TS. Hepatitis C virus core and envelope proteins do not suppress the host's ability to clear a hepatic viral infection. J Virol 2001; 75(24):11992-11998.